Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Free Cash Flow (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Free Cash Flow for 8 consecutive years, with -$11.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 39.99% to -$11.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$65.9 million through Dec 2025, down 12.32% year-over-year, with the annual reading at -$65.9 million for FY2025, 12.32% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$11.3 million at Precision Biosciences, up from -$15.3 million in the prior quarter.
  • The five-year high for Free Cash Flow was $66.9 million in Q1 2021, with the low at -$33.0 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$13.8 million, with a median of -$19.7 million recorded in 2025.
  • The sharpest move saw Free Cash Flow surged 347.83% in 2021, then plummeted 183.57% in 2023.
  • Over 5 years, Free Cash Flow stood at -$25.2 million in 2021, then rose by 10.76% to -$22.5 million in 2022, then soared by 62.64% to -$8.4 million in 2023, then tumbled by 123.65% to -$18.8 million in 2024, then skyrocketed by 39.99% to -$11.3 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$11.3 million, -$15.3 million, and -$20.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.